Global /United States /Healthcare /Biotechnology /MNMD

Mind Medicine (MindMed) Inc.

MNMD

• NASDAQ: MNMD • Delayed

15.02USD 1%

As of 15 June 2026, Mind Medicine (MindMed) Inc. has a market cap of $1.48B USD, ranking #8531 globally and #1903 in the United States. It ranks #717 in the Healthcare sector, and #139 in the Biotechnology industry.

Global Rank

8531

Country Rank

1903

Sector Rank

717

Industry Rank

139

Key Stats

Market Cap

$1.48BUSD

Enterprise Value

$1.3BUSD

EBITDA (TTM)

-$151.67MUSD

Net Income (TTM)

-$168.1MUSD

PB Ratio

8.7

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Robert Barrow open_in_new

Employees

Founded

2019

Website

mindmed.co open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1%	7.1%	20%	23%	86%	12%	131%	359%	-65%

News

MNMD Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	MNMD Mind Medicine Inc Ordinary Shares ISIN: CA60255C8850 Shares Out.: Shares Outstanding: 75.553M¹ Shares Float: 73.438M² TV: TradingView: NASDAQ: MNMD SA: Stock Analysis: NASDAQ: MNMD YF: Yahoo Finance: MNMD GF: Google Finance: NASDAQ: MNMD NQ: NASDAQ: MNMD BA: Barron's: MNMD MS: Morningstar: XNAS: MNMD	15.02 USD	TV: TradingView: NASDAQ: MNMD SA: Stock Analysis: NASDAQ: MNMD YF: Yahoo Finance: MNMD GF: Google Finance: NASDAQ: MNMD NQ: NASDAQ: MNMD BA: Barron's: MNMD MS: Morningstar: XNAS: MNMD

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 12K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 11K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 2K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 2K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 2K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 1K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 3K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.92B 68.19T KRW 3K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.46B 60.27B AUD 3K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 3K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.17B 42.76T KRW 2K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 2K%	-	Germany

chevron_leftBack